Related Experiment Videos
The contemporary management of acute myocardial infarction
F Q Almeda1, R J Snell, J E Parrillo
1Division of Cardiovascular Disease and Critical Care Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA. jonola@aol.com
Insights
Optimizing acute myocardial infarction treatment focuses on rapid reperfusion strategies. Newer therapies like low molecular weight heparin and glycoprotein IIb/IIIa inhibitors show promise, but optimal combinations require further study.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Acute myocardial infarction (AMI) management is rapidly evolving.
- Timely, complete, and sustained myocardial reperfusion is the primary therapeutic goal.
- Time is a critical factor influencing mortality in AMI.
Purpose of the Study:
- To review current and emerging strategies for myocardial reperfusion in AMI.
- To discuss the comparative efficacy of primary percutaneous coronary intervention versus thrombolysis.
- To evaluate the role of newer pharmacologic agents in AMI management.
Main Methods:
- Review of contemporary therapeutic options for AMI.
- Comparison of primary percutaneous balloon angioplasty and thrombolysis.
- Assessment of newer thrombolytic agents, low molecular weight heparin, and glycoprotein IIb/IIIa inhibitors.
- Discussion of combination therapy strategies and ongoing clinical trials.
Main Results:
- Newer thrombolytic agents offer equivalent reperfusion to alteplase (tPA) with simpler dosing.
- Low molecular weight heparin demonstrates superiority over unfractionated heparin.
- Glycoprotein IIb/IIIa inhibitors reduce complication rates in acute coronary syndromes but optimal use is debated.
- Combination therapies show potential for maximal reperfusion, pending large trial results.
Conclusions:
- Optimal AMI management requires balancing reperfusion time and likelihood.
- Risk stratification is essential for tailoring therapy.
- The choice of reperfusion strategy and pharmacologic agents remains complex, necessitating careful selection from available options.
Abstract:
The contemporary management of acute myocardial infarction continues to evolve rapidly. The ultimate goal of therapy is timely, complete, and sustained myocardial reperfusion. There is a powerful time-dependent effect on mortality, and thus the balance between the time and likelihood of maximal reperfusion is crucial in deciding whether to use primary percutaneous balloon angioplasty or thrombolysis as the initial reperfusion strategy. Newer thrombolytic agents allow for equivalent coronary reperfusion compared with the standard accelerated alteplase (tPA) regimen with the advantage of easier dosing regimens. Low molecular weight heparin has been shown to be superior to unfractionated heparin and likely will be the standard of care in the near future. The use of glycoprotein IIb/IIIa inhibitors has been shown to decrease the short- and long-term complication rates in patients with acute coronary syndromes treated medically and with percutaneous coronary interventions; however, the choice of the optimal agent and dosing regimen in various clinical settings remains controversial. Combination therapy with low-dose fibrinolytics, glycoprotein IIb/IIIa inhibitors, and low molecular weight heparin, with or without subsequent early planned percutaneous coronary interventions, may provide the optimal strategy for maximal coronary reperfusion, but the results of large, randomized mortality trials currently underway need to be analyzed. Risk stratification will continue to play a major role in determining which patients should receive a specific therapy. The care of the patient with an acute myocardial infarction will continue to be a challenge requiring the proper selection from the vast pharmaceutic and interventional options available.